|Bid||530.60 x 900|
|Ask||530.87 x 800|
|Day's Range||522.27 - 532.98|
|52 Week Range||430.24 - 589.32|
|Beta (3Y Monthly)||1.29|
|PE Ratio (TTM)||55.32|
|Earnings Date||Jul 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||578.60|
JNJ earnings report could be a boon for medical stocks Boston Scientific and Penumbra, an analyst said Wednesday. Boston has efforts in electrophysiology. Penumbra works in stroke treatment.
Intuitive Surgical (ISRG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Intuitive Surgical's (ISRG) acquisition of Scholly Fiberoptic's robotic endoscope business to likely boost the acquirer's da Vinci Surgical system.
Intuitive (ISRG), the pioneer and a global leader in robotic-assisted, minimally invasive surgery and manufacturer of da Vinci surgical systems, today announced the acquisition of Schölly Fiberoptic’s robotic endoscope business. Intuitive is acquiring the robotic endoscope portion of Schölly Fiberoptic’s business.
In 2010 Gary Guthart was appointed CEO of Intuitive Surgical, Inc. (NASDAQ:ISRG). This analysis aims first to contrast...
Last week was a quiet one for the biotech space with the exception of a few clinical trial readouts . Pharma and biotech stocks took comfort in a ruling by a federal judge that went against President Donald ...
Intuitive Surgical (ISRG) closed the most recent trading day at $526.25, moving -1.82% from the previous trading session.
While the broad U.S. equity market is pushing confidently to new all-time highs, healthcare stocks are lagging badly. The entire sector has come under pressure after President Donald Trump's effort to lower drug prices high a legal roadblock when a judge blocked a new requirement to list prices in commercials. The Trump Administration also reversed its plan to curb drug rebates for government healthcare plans.The pressure isn't slowing down, with the Health Care Select SPDR (NYSEARCA:XLV) cutting down out of a multi-week consolidation range to put an end to a three-month uptrend. This also marks a turnaround at resistance from the early December highs and sets up a decline back to the mid-April lows. * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond A number of big players in the sector are lagging badly. Here are four healthcare stocks to sell now:InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare Stocks to Sell: Johnson & Johnson (JNJ)Shares of Johnson & Johnson (NYSE:JNJ) are dropping hard, down more than 4% on Friday as I write this and returning to lows not seen since early June. The move cuts below the stock's 200-day moving average and marks an inability to challenge the prior highs from back in December. The company continues to be dogged by legal risks related to baby powder asbestos claims.The company will next report results on July 16 before the bell. Analysts are looking for earnings of $2.42 per share on revenues of $20.4 billion. When the company last reported on April 16, earnings of $2.10 beat estimates by six cents on a 0.1% rise in revenues. Abbott Laboratories (ABT)Abbott Laboratories (NYSE:ABT) shares have fallen below their 20-day moving average for the first time since late May in what looks like the latest pullback within a secular uptrend that has been in play since 2016. Barclays analysts recently highlighted the company's impressive 7.1% organic revenue growth rate but noted very high investor expectations. Some profit taking should be expected. * 10 Stocks Driving the Market to All-Time Highs (And Why) The company will next report results on July 17 before the bell. Analysts are looking for earnings of 80 cents per share on revenues of $8 billion. When the company last reported on April 17, earnings of 63 cents per share beat estimates by a penny on a 2% rise in revenues. Intuitive Surgical (ISRG)Shares of Intuitive Surgical (NASDAQ:ISRG) are threatening to fall back below their 200-day moving average after struggling to reclaim that level after a nasty 22% decline from its mid-April high. This marks a continuation of a sideways range going back to the summer of 2018. The company is a maker of robotic surgical systems.The company will next report results on July 18 after the close. Analysts are looking for earnings of $2.87 per share on revenues of just over $1 billion. When the company last reported on April 18, earnings of $2.61 missed estimates by nine cents on a 14.9% rise in revenues. Illumnia (ILMN)Shares of Illumnia (NASDAQ:ILMN), which provides sequencing solutions for genetic analysis, is suffering a decline of more than 16% in mid-day trading after management guided second-quarter revenues below consensus estimates. Sales growth was impacted by lower than expected contributions from genomics initiatives. Shares were downgraded by analysts at Bank of America Merrill Lynch from buy to sell. Earlier this week, the stock hit an all-time high. * 7 Retail Stocks to Buy for the Second Half of 2019 ISRG stock will next report results on July 29 after the close. Analysts are looking for earnings of $1.42 per share on revenues of $885.6 million. When the company last reported on April 25, earnings of $2.56 beat estimates by 30 cents per share on an 8.2% rise in revenues.As of this writing, William Roth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy for Less Than Book * 7 Marijuana Stocks With Critical Levels to Watch * The 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond The post 4 Healthcare Stocks That Are Feeling Sick Â appeared first on InvestorPlace.
Intuitive (ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced Sal Brogna’s intent to transition from his role as Executive Vice President and Chief Operating Officer. Brogna will remain with Intuitive through the end of 2019 and plans to serve as a consultant and advisor to the company starting in 2020. Brogna joined Intuitive in October 1999 and held a number of key roles in the organization over the course of his career, including Executive Vice President of Product Operations, Senior Vice President of Product Development and Vice President of Engineering.
Intuitive Surgical (ISRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Your mom might have told you to never judge people by their looks. But it's OK to do so when it comes to when to sell top stocks. Use stock charts to your advantage.
Bullish chart patterns across the robotics and automation segment of the market suggest that now could be an ideal time to buy.
Charts in the robotics and artificial intelligence industries suggest that better entry points for bulls could be a few weeks or months away.
The other day I saw an article in Forbes by value investor John Dorfman that examined four stocks to buy with little debt and high profitability. The stocks mentioned were National Beverage (NASDAQ:FIZZ), Gentex (NASDAQ:GNTX), Cactus (NYSE:WHD) and Deckers Outdoor (NASDAQ:DECK). Of Dorfman's four picks, I'm familiar with three of them. Cactus is the outlier of the group. It turns out the company makes wellheads and flow control products for the energy industry. InvestorPlace - Stock Market News, Stock Advice & Trading TipsYou learn something new every day in this business.Anyway, I'm always on the lookout for a good story idea, so I thought I'd run with Dorfman's theme and come up with seven S&P 500 stocks to buy that have little debt and lots of profits. * 6 Stocks Ready to Bounce on a Trade Deal To qualify, a company must have a debt-to-equity ratio of 20% or less and a return on equity 15% or higher. S&P 500 Stocks to Buy: Monster Beverage (MNST)Source: Mike Mozart via Flickr (modified)Monster Beverage (NASDAQ:MNST), one of the world's leading makers of energy drinks, has zero debt, $880 million in cash and marketable securities, and a return on equity of 28.6%. After conquering the energy drinks field, Monster is looking to capture a big chunk of the cannabis- and alcoholic-beverage markets. According to the Wall Street Journal, Monster is said to be interested in rolling out hard seltzers, malt beverages, and cannabis beverages once its non-compete (it's precluded from producing non-energy drinks) clause with Coca-Cola (NYSE:KO) ends in 2020. "This move actually makes a lot of sense for the company because Coke is looking more and more like a threat. In April, the brand debuted Coca-Cola Energy in Spain and Hungary, and it already sounds healthier than Monster," Delish reported June 12. Nobody thought Monster would rule the energy drink business, but here it is. I wouldn't bet against CEO and co-founder Rodney Sacks. He knows a thing or two about winning in the beverage biz. Foot Locker (FL)Source: Shutterstock Foot Locker (NYSE:FL), has gotten hammered in the past month, down approximately 25%. Nonetheless, the global retailer of sneakers has a remarkably strong balance sheet with $123 million in long-term debt, cash and cash equivalents of $1.1 billion and a return on equity of 26.9%. How do you lose 25% in a single month?Well, in Foot Locker's case, it missed analysts' first-quarter earnings estimate by eight cents. That's right, the consensus was $1.61, and FL came in at $1.53. On the top line, analysts were expecting sales of $2.11 billion; Foot Locker delivered revenues that were $33 million lower than expected. Hardly a bad earnings result -- comps rose by 4.6% during the quarter, suggesting to me that the long-term goals it has in place will surely be met. * 7 Value Stocks to Buy for the Second Half In the meantime, FL stock gives you a dividend yield of 3.7% and trading at 8.1 times its forward earnings.Can you say value stock? I knew you could. Hormel Foods (HRL)Source: Mike Mozart via Flickr (Modified)It's only appropriate that a pescetarian such as myself recommend a stock like Hormel Foods (NYSE:HRL), the makers of Spam, the most disgusting meat-based product ever created. No matter. The company has a great balance sheet with just $257.1 million in long-term debt, $639.3 million in cash and cash equivalents, and a return on equity of 19.5%.As I said, Spam is a horrible product, but a particular segment of the population seems to love it, and it pays the bills. In the first six months of 2019, Hormel's total segment profit was $615.4 million on $4.7 billion in sales, an operating profit of 13.1%. The meat-based food company is slowly making its way into plant-based foods such as a vegan pizza topping to meet the needs of consumers. While not at the front of the pack, it's working hard behind the scenes to deliver for its customers. "We understand that it is a shiny new toy," CEO Jim Snee said at a food conference in Paris recently. "We get that. It is one of our shiny new toys as well. It is something that is certainly on our minds like it is everyone else, and there is a lot of work happening both in the market and behind the scenes."Perhaps there is life after Spam. SVB Financial (SIVB)Source: Shutterstock SVB Financial (NASDAQ:SIVB) is my favorite American bank because it helps innovators and entrepreneurs around the world build their businesses.The holding company of Silicon Valley Bank has long-term debt of just $696.7 million, cash and cash equivalents of $7.1 billion, $28.9 billion in loans outstanding and a return on equity of 22.1%, which is over 800 basis points higher than JPMorgan (NYSE:JPM). In January, SIVB paid up to $340 million for Boston-based Leerink Partners LLC, an investment bank specializing in the healthcare industry. With all the changes happening in healthcare, owning a business that understands healthcare and life sciences companies, will continue to demonstrate why its a bank built on innovation. * 5 Stocks to Buy for $20 or Less Whenever it drops below $200 over the next few years, investors should buy SIVB stock. You won't regret it. Intuitive Surgical (ISRG)Source: Jon Fingas via Flickr (Modified)In February of this year, Intuitive Surgical (NASDAQ:ISRG), the makers of the da Vinci surgical system, got the green light from the FDA for Ion by Intuitive, a flexible robotic catheter that helps physicians reach "nodules in any airway segment within the lung."If you've owned ISRG stock, you're likely delighted by the news because it takes this goose beyond its golden egg. While I don't believe Intuitive is anywhere near the saturation point for its da Vinci surgical system, Ion shows it's also not a one-trick pony. That said, being a one-trick pony has made long-term shareholders very wealthy. CEO Gary Guthart owns 701,824 shares of ISRG that are worth a cool $374 million. That could buy a bunch of its surgical systems. ISRG stock hasn't done much so far in 2019, up just 13.2% year to date, but that's okay. It's got a great balance sheet with no debt, cash and marketable securities of $2.8 billion, and a return on equity of 17.9%. Long-term, I don't think you can go wrong with ISRG. A.O. Smith (AOS)Source: Nvdongen via Wikimedia (Modified)The last three years have not been kind to A.O. Smith (NYSE:AOS), the Wisconsin-based maker of water heaters, boilers and water treatment and filtration systems for both commercial and residential use. I first became interested in the company in 2012 because of its tankless water heaters. It has been so long that I can't remember exactly why I was interested in tankless water heaters. As I got to know the business, I couldn't help but recommend its stock. In recent years, AOS has significantly underperformed the S&P 500, which is unusual for a company that has delivered an annualized total return of 16.5% over the past 15 years. Unfortunately, to make matters worse, J Capital Research, a short seller intent on driving down AOS stock, made allegations against the company about its Chinese operations that suggested it was inflating sales and profits in China. The company flatly denies the allegations. All I can say is that I've followed the company's progress over the past seven years and I'm going to believe it's worth standing behind this business until proven otherwise. * 7 Top-Rated Biotech Stocks to Invest In Today As of the end of March, A.O. Smith had $277.6 million in long-term debt; $633.3 million in cash and marketable securities; and a return on equity of $20.6%. Ulta Beauty (ULTA)Source: Mike Mozart via FlickrFor almost two years, I wondered when Ulta Beauty (NASDAQ:ULTA) was going to expand to Canada. "For me, the fact that the company hasn't touched the surface when it comes to international expansion like Canada says the company's growth story is very much intact despite the headwinds it might face," I wrote on August 23, 2017. Well, the beauty retailer finally announced May 30 that it was coming to Canada, after studying various countries to figure out where it would launch its international expansion. "International expansion represents an attractive and incremental long-term growth platform, which extends our core capabilities and leverages our value proposition," CEO Mary Dillon said on Ulta's Q1 2019 conference call. "We believe that the Ulta Beauty value proposition is very relevant and differentiated in multiple geographies around the globe and Canada is an attractive and logical place to start."Dillon is one of the best retail executives in the U.S. I'm sure she will do what's best for shareholders and figure out the right pace for opening stores in Canada. Although Sephora and Shoppers Drug Mart provide competition, Ulta's in-store experience combined with top-notch online sales provides a loyal customer base that spends more.With $521.8 million in cash and marketable securities, no debt, and a return on equity of 40.9%, ULTA shareholders can look forward to more growth when it hits Canada in late 2020 or early 2021. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Blue-Chip Stocks to Buy for a Noisy Market * 5 Strong Buy Biotech Stocks for the Second Half * 6 Stocks Ready to Bounce on a Trade Deal Compare Brokers The post 7 S&P 500 Stocks to Buy With Little Debt and Lots of Profits appeared first on InvestorPlace.
David Gardner’s inspirations this week come from as far in the past as Colonial New England and as up to the minute as an icon of e-commerce.
The "patients" brought in to highlight AdventHealth's da Vinci Xi surgical robot weren't quite the usual type to walk into a hospital. The four-armed robot, which is built by Sunnyvale, California-based Intuitive Surgical Inc. (Nasdaq: ISRG), can be used by a surgeon to operate on a patient without requiring assistance from another person. As he cut into a jelly donut to seek out a gummy bear "tumor," AdventHealth Nicholson Center Chief Technical Officer Dr. Roger Smith said that the robot can make tasks easier for surgeons to do, such as holding a piece of tissue in place or having more tools available to use right away.
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
In the first quarter, Intuitive Surgical (ISRG) placed 235 da Vinci systems, a YoY (year-over-year) rise of 27.03%. However, its Systems revenue in the first quarter was $248 million, a YoY rise of 6%.
According to its first-quarter earnings conference call, Intuitive Surgical reported a 27% YoY rise in total new system placements, while its installed base rose 13% YoY net of trade exam retirements. At the end of the first quarter, the company had an installed base of 5,110.